Today, we are pleased to share with you the publication of our latest work using MCDA methodology in the Farmacia Hospitalaria journal.
This time, we used an innovative two phase approach which represents a first in Spain.
Over the two phases, we worked together with a multidisciplinary group of Spanish experts to determine the value contribution of a new HIV treatment combination (Cabotegravir + rilpivirine). Overall, a large sample of 35 Spanish experts with different backgrounds participated in the study, allowing a significant representativeness of all relevant stakeholders. We believe this approach contributed to increasing the quality of the study and robustness of results.
We invite you to check this new methodology. The manuscript is open access and can be reviewed in the following link: https://revistafarmaciahospitalaria.sefh.es/gdcr/index.php/fh/article/view/11845/pdf11845esp“
